Related Experiment Video
Updated: Feb 26, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Association of Human Methionine Synthase-A2756G Transition With Prostate Cancer: A Case-Control Study and in Silico
Arezou Ebrahimi1, Abasalt Hosseinzadeh Colagar2, Mohammad Karimian3
1Department of Biology, Faculty of Sciences, Islamic Azad University, Damghan Branch, Damghan, Iran. AND Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.
Abstract:
Methionine synthase (MTR) is one of the key enzymes of folate pathway, which play a key role in the construction, repair, and methylation of DNA. In this study, an association of MTR A2756G gene transition with prostate cancer in men populations of Kashan-Iran was investigated by a case-control study and an in silico analysis. The 200 samples including 100 patients with prostate cancer, as case group and 100 healthy men, as control group included in this study. MTR-A2756G genotyping was performed by PCR-RFLP technique. Some in silico tools used to evaluate the effects of A2756G transition on the structure and function of MTR. Results showed that the AG genotype (OR: 2.4014, 95% CI: 1.3216-4.3636, P=0.0040), and GG genotype (OR: 3.6324, 95% CI: 1.2629-10.4475, P=0.0167) and G allele (OR: 2.0120, 95% CI: 1.3098-3.0905, P=0.0014) were associated with prostate cancer. In silico analysis showed that polymorphisms of the enzyme protein might change properties of MTR such as relative mutability and flexibility, which leads to alteration of stability and function of the enzyme. Based on the results, an MTR-A2756G polymorphism which changes activity and stability of the methionine synthase associated with prostate cancer in men. It is a preliminary study and is presenting data for future comprehensive study for making a clinical conclusion that this gene transition is a biomarker for susceptibility to prostate cancer.
Insights
The methionine synthase (MTR) A2756G gene variant is linked to an increased risk of prostate cancer in men. This genetic variation may alter enzyme function, potentially serving as a biomarker for cancer susceptibility.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- The methionine synthase (MTR) enzyme is crucial for DNA methylation and repair via the folate pathway.
- Prostate cancer is a significant health concern, and understanding its genetic risk factors is vital.
Purpose of the Study:
- To investigate the association between the MTR A2756G gene polymorphism and prostate cancer risk in a Kashan-Iran male population.
- To evaluate the in silico effects of the A2756G transition on MTR enzyme structure and function.
Main Methods:
- A case-control study involving 100 prostate cancer patients and 100 healthy controls.
- Genotyping of the MTR A2756G polymorphism using the PCR-RFLP technique.
- In silico analysis to predict the impact of the polymorphism on MTR protein properties.
Main Results:
- The AG genotype (OR: 2.40, P=0.004) and GG genotype (OR: 3.63, P=0.017) of MTR A2756G were significantly associated with increased prostate cancer risk.
- The G allele also showed a significant association with prostate cancer (OR: 2.01, P=0.0014).
- In silico analysis suggested that the A2756G polymorphism may alter MTR enzyme stability and function.
Conclusions:
- The MTR A2756G polymorphism is associated with prostate cancer susceptibility in the studied male population.
- This genetic variation may influence enzyme activity and stability, contributing to cancer risk.
- Further comprehensive studies are warranted to establish this polymorphism as a clinical biomarker for prostate cancer.
